论文部分内容阅读
本研究探讨造血干细胞移植(HSCT)对恶性淋巴系统血液病的疗效。通过8例非霍奇金淋巴瘤(NHL)及3例淋巴细胞白血病患者在前期化疗基础上进行造血干细胞移植,分别观察造血重建、并发症及生存期等指标,以了解造血干细胞移植对该类疾病的疗效。结果表明:HSCT后11例患者(其中自体移植7例,异基因移植4例)造血顺利恢复,均能达到完全缓解(CR)。随访3年,5例NHL患者无病生存,1例NHL患者于移植后2个月死亡,1例自杀;4例接受异基因造血干细胞移植的患者中,1例非霍奇金淋巴瘤(NK细胞型)移植后79天死亡,1例慢性淋巴细胞白血病患者无病生存,2例急性淋巴细胞白血病患者分别于移植后第54天、第17个月死亡。结论:造血干细胞移植是治疗恶性淋巴系统血液疾病的一个有效手段,但自体HSCT的患者尚有一定的复发率,而异基因HSCT患者有可能因严重的移植相关并发症而死亡。
This study was to investigate the efficacy of hematopoietic stem cell transplantation (HSCT) on hematologic malignancies. Hematopoietic stem cell transplantation was performed on 8 patients with non-Hodgkin’s lymphoma (NHL) and 3 patients with lymphocytic leukemia on the basis of previous chemotherapy. Hematopoietic reconstitution, complications and survival were observed respectively to understand the effect of hematopoietic stem cell transplantation Efficacy of the disease. The results showed that 11 cases of HSCT (including autograft in 7 cases, allogeneic transplantation in 4 cases) successfully recovered, all achieved complete remission (CR). Five patients were followed up for 3 years. Five NHL patients were disease-free. One NHL patient died two months after transplantation and one suicide. Of the four patients who received allogeneic hematopoietic stem cell transplantation, one had non-Hodgkin’s lymphoma (NK Cell type) died 79 days after transplantation. One patient with chronic lymphocytic leukemia died of disease-free survival. Two patients with acute lymphoblastic leukemia died on the 54th and the 17th month after transplantation, respectively. CONCLUSIONS: Hematopoietic stem cell transplantation is an effective treatment for hematologic malignancies in the lymphatic system. However, patients with autologous HSCT have a relapse rate, whereas patients with allogeneic HSCT may die of severe graft-related complications.